Reset Pharma is a privately-held biotechnology company focused on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. The company’s lead program focuses on psilocybin with psychotherapy for patients with cancer related demoralization, anxiety and depression. Reset Pharma has established a highly experienced biotech development team and has a Scientific Advisory Board of leading experts in psychiatry, oncology and psychedelics.
Advancing Novel Psychedelic Medicines to Improve Mental Health in Persons with Life-threatening Illness
